Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3058% above fair value
$249.59+2.46 (+1.00%)
Close on Nov 20, 2026Market cap $36.89BP/E 106.7Yield –
Biogen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Biogen's net income for the twelve months ending Sep 30, 2026 was $347.50M, down 78.4% year over year. For fiscal 2025 it was $1.29B, down 20.8% from the year before. Over ten years it grew -9.6% a year on average. The highest annual figure on record is $5.89B in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | -20.8% |
| FY2024 | Dec 31, 2024 | $1.63B | +40.6% |
| FY2023 | Dec 31, 2023 | $1.16B | -61.9% |
| FY2022 | Dec 31, 2022 | $3.05B | +95.8% |
| FY2021 | Dec 31, 2021 | $1.56B | -61.1% |
| FY2020 | Dec 31, 2020 | $4.00B | -32.1% |
| FY2019 | Dec 31, 2019 | $5.89B | +32.9% |
| FY2018 | Dec 31, 2018 | $4.43B | +74.5% |
| FY2017 | Dec 31, 2017 | $2.54B | -31.4% |
| FY2016 | Dec 31, 2016 | $3.70B | +4.4% |
| FY2015 | Dec 31, 2015 | $3.55B | +20.9% |
| FY2014 | Dec 31, 2014 | $2.93B | +57.6% |
| FY2013 | Dec 31, 2013 | $1.86B | +34.9% |
| FY2012 | Dec 31, 2012 | $1.38B | +11.8% |
| FY2011 | Dec 31, 2011 | $1.23B | +22.8% |
| FY2010 | Dec 31, 2010 | $1.01B | +3.6% |
| FY2009 | Dec 31, 2009 | $970.13M | +23.9% |
| FY2008 | Dec 31, 2008 | $783.17M | +22.7% |
| FY2007 | Dec 31, 2007 | $638.17M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.60M | -104.4% |
| Q2 FY2026 | Jun 30, 2026 | $97.50M | -84.6% |
| Q1 FY2026 | Mar 31, 2026 | $319.50M | +32.8% |
| Q4 FY2025 | Dec 31, 2025 | -$48.90M | -118.3% |
| Q3 FY2025 | Sep 30, 2025 | $466.50M | +20.1% |
| Q2 FY2025 | Jun 30, 2025 | $634.80M | +8.8% |
| Q1 FY2025 | Mar 31, 2025 | $240.50M | -38.9% |
| Q4 FY2024 | Dec 31, 2024 | $266.70M | +6.8% |
| Q3 FY2024 | Sep 30, 2024 | $388.50M | – |
| Q2 FY2024 | Jun 30, 2024 | $583.60M | -1.4% |
| Q1 FY2024 | Mar 31, 2024 | $393.40M | +1.4% |
| Q4 FY2023 | Dec 31, 2023 | $249.70M | -54.6% |
| Q3 FY2023 | Sep 30, 2023 | -$68.10M | -106.0% |
| Q2 FY2023 | Jun 30, 2023 | $591.60M | -44.1% |
| Q1 FY2023 | Mar 31, 2023 | $387.90M | +27.7% |
| Q4 FY2022 | Dec 31, 2022 | $550.40M | +49.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.13B | +244.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.06B | +135.9% |
| Q1 FY2022 | Mar 31, 2022 | $303.80M | -25.9% |
| Q4 FY2021 | Dec 31, 2021 | $368.20M | +2.9% |
| Q3 FY2021 | Sep 30, 2021 | $329.20M | -53.1% |
| Q2 FY2021 | Jun 30, 2021 | $448.50M | -70.9% |
| Q1 FY2021 | Mar 31, 2021 | $410.20M | -70.7% |
| Q4 FY2020 | Dec 31, 2020 | $357.90M | -75.1% |
| Q3 FY2020 | Sep 30, 2020 | $701.50M | -54.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.54B | +3.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.40B | -0.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.44B | +52.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.55B | +7.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.49B | +72.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.41B | +20.1% |
| Q4 FY2018 | Dec 31, 2018 | $946.80M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.44B | +17.8% |
| Q2 FY2018 | Jun 30, 2018 | $866.60M | +0.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.17B | +56.9% |
| Q4 FY2017 | Dec 31, 2017 | -$297.40M | -145.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.23B | – |
| Q2 FY2017 | Jun 30, 2017 | $862.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $747.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $649.20M | – |
See a number that looks wrong?